| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| Other Sizes |
| Targets |
Not applicable (chiral ligand and chemical reagent). TsDPEN is a chiral ligand used in asymmetric catalysis and does not have a defined pharmacological target. It is used as a reagent for chemical synthesis rather than as a pharmacologically active compound.
|
|---|---|
| ln Vitro |
TsDPEN is a chiral ligand used in asymmetric catalysis and does not exhibit direct pharmacological activity in standard in vitro assays. It is used as a reagent for the synthesis of chiral compounds in organic chemistry.
|
| ln Vivo |
In vivo studies of TsDPEN are not applicable as the compound is a chiral ligand and chemical reagent rather than a pharmacologically active compound. It is used in chemical synthesis to produce compounds that may be evaluated in vivo.
|
| Enzyme Assay |
Non-cell-based assays for TsDPEN are primarily analytical in nature. Standard methods including HPLC, NMR, and mass spectrometry are used for identification, quantification, and purity assessment. Physicochemical properties such as melting point (128-131°C), boiling point (537.3°C), and LogP (4.59) are determined using standard protocols.
|
| Cell Assay |
Cell-based assays for TsDPEN are not commonly performed, as the compound is a chiral ligand and chemical reagent rather than a pharmacologically active compound. Compounds synthesized using this reagent may be tested in cell-based assays, but the reagent itself is not typically used in cell culture applications.
|
| Animal Protocol |
In vivo animal studies for TsDPEN are not applicable as the compound is a chiral ligand and chemical reagent rather than a pharmacologically active compound. It is used in chemical synthesis to produce compounds that may be evaluated in animal models.
|
| ADME/Pharmacokinetics |
TsDPEN has a molecular formula of C₂₁H₂₂N₂O₂S and a molecular weight of 366.48 g/mol. It has a melting point of 128-131°C, a boiling point of 537.3°C, and a LogP of 4.59. It appears as a white to off-white solid powder. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for TsDPEN are limited. As a chemical reagent, it may cause irritation to the skin, eyes, and respiratory tract. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| Additional Infomation |
See other relationships...
TsDPEN ((1R,2R)-(-)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine) is a chiral ligand that has been widely used in asymmetric catalysis. It is a biochemical compound that can be used as a biomaterial or organic/chemical reagent for biomedical research. It is also known as (R,R)-N-(2-amino-1,2-diphenylethyl)-p-toluenesulfonamide. It is for research use only. |
| Molecular Formula |
C21H22N2O2S
|
|---|---|
| Molecular Weight |
366.48
|
| Exact Mass |
366.14
|
| CAS # |
144222-34-4
|
| PubChem CID |
2734565
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
537.3±60.0 °C at 760 mmHg
|
| Melting Point |
128-131 °C(lit.)
|
| Flash Point |
278.8±32.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.627
|
| LogP |
4.59
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
511
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=CC=C(C=C1)S(=O)(=O)N[C@H](C2=CC=CC=C2)[C@@H](C3=CC=CC=C3)N
|
| InChi Key |
UOPFIWYXBIHPIP-NHCUHLMSSA-N
|
| InChi Code |
InChI=1S/C21H22N2O2S/c1-16-12-14-19(15-13-16)26(24,25)23-21(18-10-6-3-7-11-18)20(22)17-8-4-2-5-9-17/h2-15,20-21,23H,22H2,1H3/t20-,21-/m1/s1
|
| Chemical Name |
N-[(1R,2R)-2-amino-1,2-diphenylethyl]-4-methylbenzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7287 mL | 13.6433 mL | 27.2866 mL | |
| 5 mM | 0.5457 mL | 2.7287 mL | 5.4573 mL | |
| 10 mM | 0.2729 mL | 1.3643 mL | 2.7287 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
